Oramed Announces Successful FDA Phase 2a Clinical Trial Results
JERUSALEM January 30 , 201 4 — Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP ), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD - 0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Thirty patients with type 2 diabetes took part in the trial in an in - patient setting for one week. Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated against a placebo control. Further information on the safety results of the Phase 2a clinical trial can be found on Oramed’s website. Full results are expected to be presented at a scientific conference in the fut ure.
“ We are extremely pleased with the results which give a solid validation for Oramed’s platform technology in general and our oral insulin program in particular , ” stated Oramed CEO Nadav Kidron . “ Following on the results from this type 2 diabetes study we are gearing up to start a multi - center Phase 2b study later this year. W e are also excited about the potential of this drug for type 1 diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term.”
About ORMD - 0801 Oral Insulin
Oramed's ORMD - 0801 is an orally ingestible insulin capsule for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite. Moreover, orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage as well as the advantage of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD - 0801 ) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule ( ORMD - 0901; a GLP - 1 analog ). Oramed is also moving forward with clinical trials of ORMD - 0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
For more information please visit www.oramed.com
Forward - looking statements: This press release contains forward - looking statements. For example, we are using forward - looking statements when we discuss the results of our phase 2a clinical trial validating our technology platform and insulin oral program, the future announcement of the full results of this trial, our planned clinical trials , the potential of ORMD - 0801 oral insulin capsule for type 1 diabetes , or revolutionizing the treatment of diabetes with our products. These forward - looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward - looking statements, including the risks an d uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward - looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in re al settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward - looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward - looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange.
Source: Oramed Pharmaceuticals
Posted: January 2014